ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.131,97
0,32%
S&P 500
5.482,21
0,16%
Dow Jones
38.797,29
0,05%
Euro vs US Dollar
1,07366
-0,04%
Bitcoin
64.611,09
-2,82%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) News

CPRX

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CPRX
DatumZeitQuelleÜberschriftSymbolFirma
11/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
07/06/202417h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
04/06/202416h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
03/06/202418h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
31/05/202422h50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CPRXCatalyst Pharmaceuticals Inc
31/05/202422h47Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
31/05/202422h46Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
31/05/202422h43Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
30/05/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
30/05/202419h41GlobeNewswire Inc.Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®NASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/05/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
21/05/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202422h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202422h16GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
01/05/202414h00GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
22/04/202414h00GlobeNewswire Inc.Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/03/202413h03GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/03/202413h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:CPRXCatalyst Pharmaceuticals Inc
13/03/202412h55GlobeNewswire Inc.Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/03/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
29/02/202400h03GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/02/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREENASDAQ:CPRXCatalyst Pharmaceuticals Inc
21/02/202415h00GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal NeurologyNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CPRX

Kürzlich von Ihnen besucht

TG
BAS
BASF
FX
EURJPY
Euro vs Yen
NYSE
NKE
Nike
TG
MBG
MercedesBenz
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
TG
LHA
Deutsche Lufthansa
USOTC
RHHBY
Roche (QX)
DBI
MDAX
MDAX
CCOM
US30
US 30
CCOM
US500
US 500
TG
TUI1
Tui
AMEX
XLF
Financial Select Sector
COIN
SOLUSD
Solana
FX
EURGBP
Euro vs Sterling
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten